About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Change in Airway Peripheral Tone in COPD

NCT04166812·2 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Heidelberg University

With

PD Dr. Henrik Watz, Pulmonary Research Center, LungenClinic Großhansdorf (Principal Investigator)
Chiesi GmbH, Hamburg, Germany (Funding)

Age

35–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

patients at risk for COPD
smoking history (at least 10 pack years)
absence of airway obstruction (FEV1/FVC ≥ 70% after salbutamol 400µg)
high symptom score (CAT ≥ 10) or long acting bronchodilator therapy
age \> 35 years
smoking history (at least 10 pack years)
mild COPD (FEV1/FVC \< 70% and FEV1 ≥ 70% after salbutamol 400µg)
age \> 35 years

You may not be if

respiratory infection within 4 weeks prior to inclusion
other symptomatic pulmonary disease, except bronchial asthma
patients with early COPD
respiratory infection within 4 weeks prior to inclusion
other pulmonary disease, except bronchial asthma

The record

StatusUnknown

PhaseNo phase

Taking part150

StartedNov 2019

UpdatedJul 14, 2021

Conditions

COPD COPD, Early-Onset

Where2

Pulmonary Research Institute at LungClinic Großhansdorf
Großhansdorf, Germany
Thoraxklinik at Heidelberg University
Heidelberg, Germany

Clareo Health | Change in Airway Peripheral Tone in COPD